NZ548612A - Albumin fusion proteins comprising tandem GLP-1 - Google Patents

Info

Publication number

NZ548612A

NZ548612A NZ548612A NZ54861205A NZ548612A NZ 548612 A NZ548612 A NZ 548612A NZ 548612 A NZ548612 A NZ 548612A NZ 54861205 A NZ54861205 A NZ 54861205A NZ 548612 A NZ548612 A NZ 548612A

Authority

NZ

New Zealand

Prior art keywords

fusion protein

albumin

glp

albumin fusion

hsa

Prior art date

2004-02-09

Links

• Espacenet
• Global Dossier
• Discuss

• 102000009027 Albumins Human genes 0.000 title claims abstract description 470
• 108010088751 Albumins Proteins 0.000 title claims abstract description 470
• 102000037865 fusion proteins Human genes 0.000 title claims abstract description 337
• 108020001507 fusion proteins Proteins 0.000 title claims abstract description 337
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract description 23
• 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 171
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 164
• 229920001184 polypeptide Polymers 0.000 claims abstract description 160
• 239000012634 fragment Substances 0.000 claims abstract description 158
• 230000000694 effects Effects 0.000 claims abstract description 90
• 210000002966 serum Anatomy 0.000 claims abstract description 25
• 150000001413 amino acids Chemical group 0.000 claims description 110
• 102000040430 polynucleotide Human genes 0.000 claims description 108
• 108091033319 polynucleotide Proteins 0.000 claims description 108
• 239000002157 polynucleotide Substances 0.000 claims description 108
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 80
• 238000000034 method Methods 0.000 claims description 68
• 210000004027 cell Anatomy 0.000 claims description 66
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 54
• 108091006905 Human Serum Albumin Proteins 0.000 claims description 42
• 102000008100 Human Serum Albumin Human genes 0.000 claims description 42
• 206010012601 diabetes mellitus Diseases 0.000 claims description 29
• 102000004877 Insulin Human genes 0.000 claims description 27
• 108090001061 Insulin Proteins 0.000 claims description 27
• 229940125396 insulin Drugs 0.000 claims description 27
• 230000014509 gene expression Effects 0.000 claims description 26
• 230000015572 biosynthetic process Effects 0.000 claims description 25
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 21
• 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims description 20
• 230000001629 suppression Effects 0.000 claims description 20
• 241000282414 Homo sapiens Species 0.000 claims description 19
• 238000004519 manufacturing process Methods 0.000 claims description 19
• 238000003786 synthesis reaction Methods 0.000 claims description 19
• 230000028327 secretion Effects 0.000 claims description 18
• 230000004936 stimulating effect Effects 0.000 claims description 17
• 230000013595 glycosylation Effects 0.000 claims description 16
• 238000006206 glycosylation reaction Methods 0.000 claims description 16
• 239000013598 vector Substances 0.000 claims description 15
• 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 12
• 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 12
• 230000000903 blocking effect Effects 0.000 claims description 12
• 230000008569 process Effects 0.000 claims description 12
• 230000035945 sensitivity Effects 0.000 claims description 12
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
• 208000008589 Obesity Diseases 0.000 claims description 11
• 230000036528 appetite Effects 0.000 claims description 11
• 235000019789 appetite Nutrition 0.000 claims description 11
• 239000003814 drug Substances 0.000 claims description 11
• 208000015181 infectious disease Diseases 0.000 claims description 11
• 235000020824 obesity Nutrition 0.000 claims description 11
• 230000007812 deficiency Effects 0.000 claims description 10
• 230000002708 enhancing effect Effects 0.000 claims description 10
• 201000001421 hyperglycemia Diseases 0.000 claims description 10
• 208000030159 metabolic disease Diseases 0.000 claims description 10
• 208000011580 syndromic disease Diseases 0.000 claims description 10
• 208000000044 Amnesia Diseases 0.000 claims description 9
• 208000028698 Cognitive impairment Diseases 0.000 claims description 9
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 9
• 206010022489 Insulin Resistance Diseases 0.000 claims description 9
• 208000026139 Memory disease Diseases 0.000 claims description 9
• 208000017442 Retinal disease Diseases 0.000 claims description 9
• 206010038923 Retinopathy Diseases 0.000 claims description 9
• 208000025865 Ulcer Diseases 0.000 claims description 9
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 9
• 230000037396 body weight Effects 0.000 claims description 9
• 208000010877 cognitive disease Diseases 0.000 claims description 9
• 201000010064 diabetes insipidus Diseases 0.000 claims description 9
• 230000001079 digestive effect Effects 0.000 claims description 9
• 230000004190 glucose uptake Effects 0.000 claims description 9
• 208000019622 heart disease Diseases 0.000 claims description 9
• 208000026278 immune system disease Diseases 0.000 claims description 9
• 210000005228 liver tissue Anatomy 0.000 claims description 9
• 230000006984 memory degeneration Effects 0.000 claims description 9
• 208000023060 memory loss Diseases 0.000 claims description 9
• 239000000203 mixture Substances 0.000 claims description 9
• 210000003205 muscle Anatomy 0.000 claims description 9
• 231100000397 ulcer Toxicity 0.000 claims description 9
• 208000019553 vascular disease Diseases 0.000 claims description 9
• 102000051325 Glucagon Human genes 0.000 claims description 8
• 108060003199 Glucagon Proteins 0.000 claims description 8
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 8
• 229960004666 glucagon Drugs 0.000 claims description 8
• 230000035861 hyperketonemia Effects 0.000 claims description 8
• 238000012545 processing Methods 0.000 claims description 8
• 210000004962 mammalian cell Anatomy 0.000 claims description 6
• 230000002950 deficient Effects 0.000 claims description 5
• 101710096444 Killer toxin Proteins 0.000 claims description 4
• 210000005253 yeast cell Anatomy 0.000 claims description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
• 101710089743 Mating factor alpha Proteins 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000001131 transforming effect Effects 0.000 claims description 2
• 241001138401 Kluyveromyces lactis Species 0.000 claims 2
• 241000235058 Komagataella pastoris Species 0.000 claims 2
• 108091005804 Peptidases Proteins 0.000 claims 2
• 239000004365 Protease Substances 0.000 claims 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
• NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 claims 1
• OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
• 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 claims 1
• 101710176384 Peptide 1 Proteins 0.000 claims 1
• 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract description 42
• GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract description 3
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 4
• 108090000623 proteins and genes Proteins 0.000 description 341
• 102000004169 proteins and genes Human genes 0.000 description 336
• 235000018102 proteins Nutrition 0.000 description 335
• 230000001225 therapeutic effect Effects 0.000 description 299
• 235000001014 amino acid Nutrition 0.000 description 116
• 229940024606 amino acid Drugs 0.000 description 91
• 230000004927 fusion Effects 0.000 description 82
• 125000003275 alpha amino acid group Chemical group 0.000 description 76
• 238000003556 assay Methods 0.000 description 65
• 102000014150 Interferons Human genes 0.000 description 53
• 108010050904 Interferons Proteins 0.000 description 53
• 229940079322 interferon Drugs 0.000 description 49
• 230000004071 biological effect Effects 0.000 description 48
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 40
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 39
• 102100040918 Pro-glucagon Human genes 0.000 description 38
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 37
• 238000006467 substitution reaction Methods 0.000 description 36
• 206010010099 Combined immunodeficiency Diseases 0.000 description 33
• 239000000427 antigen Substances 0.000 description 33
• 102000036639 antigens Human genes 0.000 description 33
• 108091007433 antigens Proteins 0.000 description 33
• 150000007523 nucleic acids Chemical class 0.000 description 33
• 206010028980 Neoplasm Diseases 0.000 description 32
• 230000027455 binding Effects 0.000 description 32
• 102000039446 nucleic acids Human genes 0.000 description 30
• 108020004707 nucleic acids Proteins 0.000 description 30
• 238000012217 deletion Methods 0.000 description 26
• 230000037430 deletion Effects 0.000 description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
• 102000006992 Interferon-alpha Human genes 0.000 description 24
• 108010047761 Interferon-alpha Proteins 0.000 description 24
• 238000011282 treatment Methods 0.000 description 24
• 210000004899 c-terminal region Anatomy 0.000 description 23
• 210000002381 plasma Anatomy 0.000 description 23
• 102000007562 Serum Albumin Human genes 0.000 description 21
• 108010071390 Serum Albumin Proteins 0.000 description 21
• 125000000539 amino acid group Chemical group 0.000 description 21
• 101150007193 IFNB1 gene Proteins 0.000 description 19
• 108010092464 Urate Oxidase Proteins 0.000 description 18
• 238000011144 upstream manufacturing Methods 0.000 description 18
• 201000011510 cancer Diseases 0.000 description 17
• 201000010099 disease Diseases 0.000 description 16
• 101150045458 KEX2 gene Proteins 0.000 description 15
• 125000003729 nucleotide group Chemical group 0.000 description 15
• -1 antibody Proteins 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• 230000000747 cardiac effect Effects 0.000 description 13
• 239000013604 expression vector Substances 0.000 description 13
• 210000002700 urine Anatomy 0.000 description 13
• 206010019280 Heart failures Diseases 0.000 description 12
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
• 230000005714 functional activity Effects 0.000 description 12
• 230000004048 modification Effects 0.000 description 12
• 238000012986 modification Methods 0.000 description 12
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
• 108010002350 Interleukin-2 Proteins 0.000 description 11
• 102000000588 Interleukin-2 Human genes 0.000 description 11
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
• 239000008103 glucose Substances 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 239000011734 sodium Substances 0.000 description 11
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 10
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 10
• 108020004705 Codon Proteins 0.000 description 10
• 102000006397 Ephrin-B1 Human genes 0.000 description 10
• 108010044099 Ephrin-B1 Proteins 0.000 description 10
• 102000002265 Human Growth Hormone Human genes 0.000 description 10
• 108010000521 Human Growth Hormone Proteins 0.000 description 10
• 239000000854 Human Growth Hormone Substances 0.000 description 10
• 206010020772 Hypertension Diseases 0.000 description 10
• 101710173438 Late L2 mu core protein Proteins 0.000 description 10
• 101710188315 Protein X Proteins 0.000 description 10
• 229960002478 aldosterone Drugs 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 239000000122 growth hormone Substances 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 108010082340 Arginine deiminase Proteins 0.000 description 9
• 208000024172 Cardiovascular disease Diseases 0.000 description 9
• 102100040019 Interferon alpha-1/13 Human genes 0.000 description 9
• 108010078049 Interferon alpha-2 Proteins 0.000 description 9
• 108090000467 Interferon-beta Proteins 0.000 description 9
• 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 9
• 208000004880 Polyuria Diseases 0.000 description 9
• 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 9
• 101710178416 Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 230000035619 diuresis Effects 0.000 description 9
• 238000003018 immunoassay Methods 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 9
• 235000002639 sodium chloride Nutrition 0.000 description 9
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
• 102000004379 Adrenomedullin Human genes 0.000 description 8
• 101800004616 Adrenomedullin Proteins 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 8
• 206010007559 Cardiac failure congestive Diseases 0.000 description 8
• 102000018997 Growth Hormone Human genes 0.000 description 8
• 108010051696 Growth Hormone Proteins 0.000 description 8
• 102100040018 Interferon alpha-2 Human genes 0.000 description 8
• 101710106107 Interferon alpha-D Proteins 0.000 description 8
• 102400001283 Long-acting natriuretic peptide Human genes 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 208000002193 Pain Diseases 0.000 description 8
• ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 8
• 239000003443 antiviral agent Substances 0.000 description 8
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
• 229960002986 dinoprostone Drugs 0.000 description 8
• 238000009396 hybridization Methods 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 239000001573 invertase Substances 0.000 description 8
• 235000011073 invertase Nutrition 0.000 description 8
• 230000002132 lysosomal effect Effects 0.000 description 8
• 230000036407 pain Effects 0.000 description 8
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• 101710170757 Acidic leucine-rich nuclear phosphoprotein 32 family member A Proteins 0.000 description 7
• 208000009304 Acute Kidney Injury Diseases 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 208000022461 Glomerular disease Diseases 0.000 description 7
• 108010017544 Glucosylceramidase Proteins 0.000 description 7
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 102000003996 Interferon-beta Human genes 0.000 description 7
• 208000033626 Renal failure acute Diseases 0.000 description 7
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 7
• 201000011040 acute kidney failure Diseases 0.000 description 7
• 208000012998 acute renal failure Diseases 0.000 description 7
• 230000000840 anti-viral effect Effects 0.000 description 7
• 238000010494 dissociation reaction Methods 0.000 description 7
• 230000005593 dissociations Effects 0.000 description 7
• 231100000852 glomerular disease Toxicity 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 238000003752 polymerase chain reaction Methods 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 230000029865 regulation of blood pressure Effects 0.000 description 7
• 229910052708 sodium Inorganic materials 0.000 description 7
• 230000025033 vasoconstriction Effects 0.000 description 7
• 230000024883 vasodilation Effects 0.000 description 7
• 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 6
• 108010050286 Dendroaspis natriuretic peptide Proteins 0.000 description 6
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 206010038540 Renal tubular necrosis Diseases 0.000 description 6
• 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 208000036142 Viral infection Diseases 0.000 description 6
• 230000033115 angiogenesis Effects 0.000 description 6
• 210000001124 body fluid Anatomy 0.000 description 6
• 239000010839 body fluid Substances 0.000 description 6
• 238000001516 cell proliferation assay Methods 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• 238000005755 formation reaction Methods 0.000 description 6
• 230000002163 immunogen Effects 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 208000017169 kidney disease Diseases 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
• 230000000717 retained effect Effects 0.000 description 6
• 229960000329 ribavirin Drugs 0.000 description 6
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
• 150000003839 salts Chemical class 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 230000009385 viral infection Effects 0.000 description 6
• 238000005406 washing Methods 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 229910001868 water Inorganic materials 0.000 description 6
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
• 102100031478 C-type natriuretic peptide Human genes 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 208000000059 Dyspnea Diseases 0.000 description 5
• 206010013975 Dyspnoeas Diseases 0.000 description 5
• 241001115402 Ebolavirus Species 0.000 description 5
• 206010016803 Fluid overload Diseases 0.000 description 5
• 241000711549 Hepacivirus C Species 0.000 description 5
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 5
• 208000004454 Hyperalgesia Diseases 0.000 description 5
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 5
• 206010029350 Neurotoxicity Diseases 0.000 description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
• 206010044221 Toxic encephalopathy Diseases 0.000 description 5
• 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000001028 anti-proliverative effect Effects 0.000 description 5
• 239000011324 bead Substances 0.000 description 5
• 230000036772 blood pressure Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 238000002591 computed tomography Methods 0.000 description 5
• 230000009260 cross reactivity Effects 0.000 description 5
• 239000003792 electrolyte Substances 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 201000007270 liver cancer Diseases 0.000 description 5
• 208000014018 liver neoplasm Diseases 0.000 description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 231100000228 neurotoxicity Toxicity 0.000 description 5
• 230000007135 neurotoxicity Effects 0.000 description 5
• 201000002528 pancreatic cancer Diseases 0.000 description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000004648 relaxation of smooth muscle Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 238000002604 ultrasonography Methods 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• 206010005949 Bone cancer Diseases 0.000 description 4
• 208000018084 Bone neoplasm Diseases 0.000 description 4
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 206010056438 Growth hormone deficiency Diseases 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 241000204031 Mycoplasma Species 0.000 description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
• 208000003152 Yellow Fever Diseases 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000004075 alteration Effects 0.000 description 4
• 230000008827 biological function Effects 0.000 description 4
• 208000029742 colonic neoplasm Diseases 0.000 description 4
• 238000012875 competitive assay Methods 0.000 description 4
• 230000008602 contraction Effects 0.000 description 4
• 230000000120 cytopathologic effect Effects 0.000 description 4
• 230000010339 dilation Effects 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 229940047124 interferons Drugs 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 208000020816 lung neoplasm Diseases 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000007514 neuronal growth Effects 0.000 description 4
• 150000002482 oligosaccharides Polymers 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical group CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 102000013563 Acid Phosphatase Human genes 0.000 description 3
• 108010051457 Acid Phosphatase Proteins 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 241000712891 Arenavirus Species 0.000 description 3
• 241001536481 Banzi virus Species 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
• 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 3
• 239000003155 DNA primer Substances 0.000 description 3
• 241000710829 Dengue virus group Species 0.000 description 3
• 241000710945 Eastern equine encephalitis virus Species 0.000 description 3
• 241000709661 Enterovirus Species 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 206010066919 Epidemic polyarthritis Diseases 0.000 description 3
• 241000711950 Filoviridae Species 0.000 description 3
• 241000710831 Flavivirus Species 0.000 description 3
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 108010086677 Gonadotropins Proteins 0.000 description 3
• 102000006771 Gonadotropins Human genes 0.000 description 3
• 241000190708 Guanarito mammarenavirus Species 0.000 description 3
• 241000893570 Hendra henipavirus Species 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 108010005716 Interferon beta-1a Proteins 0.000 description 3
• 241000710842 Japanese encephalitis virus Species 0.000 description 3
• 241000712890 Junin mammarenavirus Species 0.000 description 3
• 241001466978 Kyasanur forest disease virus Species 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• 241000713102 La Crosse virus Species 0.000 description 3
• 241000712902 Lassa mammarenavirus Species 0.000 description 3
• 241000712898 Machupo mammarenavirus Species 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 241001115401 Marburgvirus Species 0.000 description 3
• 201000005505 Measles Diseases 0.000 description 3
• 208000007201 Myocardial reperfusion injury Diseases 0.000 description 3
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
• 241000526636 Nipah henipavirus Species 0.000 description 3
• 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 3
• 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 3
• 241000150452 Orthohantavirus Species 0.000 description 3
• 241001504519 Papio ursinus Species 0.000 description 3
• 241000713126 Punta Toro virus Species 0.000 description 3
• 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 description 3
• 241000713124 Rift Valley fever virus Species 0.000 description 3
• 241000710942 Ross River virus Species 0.000 description 3
• 241000710799 Rubella virus Species 0.000 description 3
• 241000315672 SARS coronavirus Species 0.000 description 3
• 241001135555 Sandfly fever Sicilian virus Species 0.000 description 3
• 241000710961 Semliki Forest virus Species 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 206010046865 Vaccinia virus infection Diseases 0.000 description 3
• 241000700647 Variola virus Species 0.000 description 3
• 206010047139 Vasoconstriction Diseases 0.000 description 3
• 208000033774 Ventricular Remodeling Diseases 0.000 description 3
• 208000028227 Viral hemorrhagic fever Diseases 0.000 description 3
• 241000710886 West Nile virus Species 0.000 description 3
• 241000710951 Western equine encephalitis virus Species 0.000 description 3
• 238000007818 agglutination assay Methods 0.000 description 3
• 238000002832 anti-viral assay Methods 0.000 description 3
• 238000004166 bioassay Methods 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 102220364140 c.55A>G Human genes 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 201000003740 cowpox Diseases 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 230000001747 exhibiting effect Effects 0.000 description 3
• LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000002622 gonadotropin Substances 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000001114 immunoprecipitation Methods 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 108010010648 interferon alfacon-1 Proteins 0.000 description 3
• 229960001388 interferon-beta Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 208000005871 monkeypox Diseases 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 229920001542 oligosaccharide Polymers 0.000 description 3
• 238000007410 oral glucose tolerance test Methods 0.000 description 3
• 229920002401 polyacrylamide Polymers 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 239000013615 primer Substances 0.000 description 3
• 230000004853 protein function Effects 0.000 description 3
• 108010084837 rasburicase Proteins 0.000 description 3
• 230000000241 respiratory effect Effects 0.000 description 3
• 102220062667 rs779791579 Human genes 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 241001529453 unidentified herpesvirus Species 0.000 description 3
• 208000007089 vaccinia Diseases 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 108010039627 Aprotinin Proteins 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 230000005788 Cochlea function Effects 0.000 description 2
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
• 208000001528 Coronaviridae Infections Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 2
• 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• 206010050394 Hyperkaliuria Diseases 0.000 description 2
• 206010058359 Hypogonadism Diseases 0.000 description 2
• 206010021067 Hypopituitarism Diseases 0.000 description 2
• 206010022095 Injection Site reaction Diseases 0.000 description 2
• 102100039729 Interferon alpha-21 Human genes 0.000 description 2
• 102100036532 Interferon alpha-8 Human genes 0.000 description 2
• 101710106105 Interferon alpha-F Proteins 0.000 description 2
• 102100026720 Interferon beta Human genes 0.000 description 2
• 102100034845 KiSS-1 receptor Human genes 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 241000282560 Macaca mulatta Species 0.000 description 2
• 208000029725 Metabolic bone disease Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 102400001124 Metastin Human genes 0.000 description 2
• 238000012347 Morris Water Maze Methods 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 241000713112 Orthobunyavirus Species 0.000 description 2
• 241000700629 Orthopoxvirus Species 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 206010049088 Osteopenia Diseases 0.000 description 2
• 241000282577 Pan troglodytes Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 108090000783 Renin Proteins 0.000 description 2
• 102100028255 Renin Human genes 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 108010014401 TWEAK Receptor Proteins 0.000 description 2
• 102000016946 TWEAK Receptor Human genes 0.000 description 2
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 108700025316 aldesleukin Proteins 0.000 description 2
• 108010060162 alglucerase Proteins 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
• 206010053552 allodynia Diseases 0.000 description 2
• 150000001408 amides Chemical group 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 229940003504 avonex Drugs 0.000 description 2
• 238000002869 basic local alignment search tool Methods 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 238000004422 calculation algorithm Methods 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 239000013599 cloning vector Substances 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000005860 defense response to virus Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 206010016165 failure to thrive Diseases 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 238000005227 gel permeation chromatography Methods 0.000 description 2
• 238000012817 gel-diffusion technique Methods 0.000 description 2
• 238000002873 global sequence alignment Methods 0.000 description 2
• 208000031169 hemorrhagic disease Diseases 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 2
• 108010039650 imiglucerase Proteins 0.000 description 2
• 230000006303 immediate early viral mRNA transcription Effects 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000000951 immunodiffusion Effects 0.000 description 2
• 229940090438 infergen Drugs 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229960003507 interferon alfa-2b Drugs 0.000 description 2
• 108010006088 interferon alfa-n1 Proteins 0.000 description 2
• 108010047126 interferon-alpha 8 Proteins 0.000 description 2
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 230000036230 kaliuresis Effects 0.000 description 2
• 238000012933 kinetic analysis Methods 0.000 description 2
• 230000013016 learning Effects 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 238000001823 molecular biology technique Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• 230000036963 noncompetitive effect Effects 0.000 description 2
• 229940063149 nutropin Drugs 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229940002988 pegasys Drugs 0.000 description 2
• 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
• 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
• 229940106366 pegintron Drugs 0.000 description 2
• 230000006320 pegylation Effects 0.000 description 2
• 230000007030 peptide scission Effects 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
• 238000010798 ubiquitination Methods 0.000 description 2
• 230000034512 ubiquitination Effects 0.000 description 2
• 229940116269 uric acid Drugs 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• URJOZSLMTIRWFW-QGZVFWFLSA-N (4r)-4-(1,3-benzodioxol-5-yl)-5,6-dimethoxy-4,9-dihydro-1h-benzo[f][2]benzofuran-3-one Chemical compound C1=C2OCOC2=CC([C@H]2C3=C(COC3=O)CC3=CC=C(C(=C32)OC)OC)=C1 URJOZSLMTIRWFW-QGZVFWFLSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• ZWXONJFCJAGEBA-BXWFABGCSA-N 4-[2-(5-Hydroxy-2-methylphenyl)ethyl]-7a-methylhexahydro-1H-indene-1,5(4H)-dione Chemical compound CC1=CC=C(O)C=C1CC[C@@H]1C(=O)CC[C@]2(C)C(=O)CC[C@H]21 ZWXONJFCJAGEBA-BXWFABGCSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• 230000005730 ADP ribosylation Effects 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 102220470467 Adenosine 5'-monophosphoramidase HINT2_C38S_mutation Human genes 0.000 description 1
• 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
• POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
• 201000000736 Amenorrhea Diseases 0.000 description 1
• 206010001928 Amenorrhoea Diseases 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 241000557639 Araucaria bidwillii Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
• 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010070237 Burning feet syndrome Diseases 0.000 description 1
• 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 1
• 101800000060 C-type natriuretic peptide Proteins 0.000 description 1
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000001387 Causalgia Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010064012 Central pain syndrome Diseases 0.000 description 1
• YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 208000026845 Cochlear disease Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 206010013883 Dwarfism Diseases 0.000 description 1
• 208000004483 Dyspareunia Diseases 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000024720 Fabry Disease Diseases 0.000 description 1
• 208000007984 Female Infertility Diseases 0.000 description 1
• 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010017076 Fracture Diseases 0.000 description 1
• 208000036119 Frailty Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 102400000320 Glicentin Human genes 0.000 description 1
• 101800002945 Glicentin Proteins 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
• 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
• 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
• 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
• 108010056771 Glucosidases Proteins 0.000 description 1
• 102000004366 Glucosidases Human genes 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 230000010556 Heparin Binding Activity Effects 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 108700027089 Hirudo medicinalis macrolin Proteins 0.000 description 1
• 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 1
• 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
• 101500026282 Homo sapiens Metastin Proteins 0.000 description 1
• 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 1
• 208000033830 Hot Flashes Diseases 0.000 description 1
• 206010060800 Hot flush Diseases 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 201000001431 Hyperuricemia Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 206010021928 Infertility female Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000027601 Inner ear disease Diseases 0.000 description 1
• 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
• 108010005714 Interferon beta-1b Proteins 0.000 description 1
• 108010079944 Interferon-alpha2b Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 102400001285 Kaliuretic peptide Human genes 0.000 description 1
• 201000007493 Kallmann syndrome Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 108010012048 Kisspeptins Proteins 0.000 description 1
• 208000000588 Klippel-Trenaunay-Weber Syndrome Diseases 0.000 description 1
• 208000034642 Klippel-Trénaunay syndrome Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
• 206010024870 Loss of libido Diseases 0.000 description 1
• 208000015439 Lysosomal storage disease Diseases 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 241001553014 Myrsine salicina Species 0.000 description 1
• SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
• YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
• 241001481166 Nautilus Species 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
• 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
• 208000035175 Oligomenorrhea Diseases 0.000 description 1
• 206010030295 Oligomenorrhoea Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 102400000319 Oxyntomodulin Human genes 0.000 description 1
• 101800001388 Oxyntomodulin Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000002141 Pellagra Diseases 0.000 description 1
• 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 1
• 101710189920 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Proteins 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• 206010056238 Phantom pain Diseases 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
• 102400000980 Pituitary adenylate cyclase-activating polypeptide 27 Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 208000004550 Postoperative Pain Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 101710150593 Protein beta Proteins 0.000 description 1
• 108010012770 Rebetron Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
• 241000084978 Rena Species 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 206010059594 Secondary hypogonadism Diseases 0.000 description 1
• 108010086019 Secretin Proteins 0.000 description 1
• 102100037505 Secretin Human genes 0.000 description 1
• 102000040739 Secretory proteins Human genes 0.000 description 1
• 108091058545 Secretory proteins Proteins 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 208000001163 Tangier disease Diseases 0.000 description 1
• 102100028644 Tenascin-R Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
• 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
• 208000009205 Tinnitus Diseases 0.000 description 1
• 102100024276 Transcription factor SOX-3 Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 208000026928 Turner syndrome Diseases 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000012886 Vertigo Diseases 0.000 description 1
• 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
• 208000027276 Von Willebrand disease Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
• 229960005310 aldesleukin Drugs 0.000 description 1
• 229960003122 alglucerase Drugs 0.000 description 1
• 229960000458 allantoin Drugs 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 231100000540 amenorrhea Toxicity 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 208000012948 angioosteohypertrophic syndrome Diseases 0.000 description 1
• 230000001565 angiopathic effect Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 229910052785 arsenic Inorganic materials 0.000 description 1
• RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 230000035045 associative learning Effects 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 108010073970 atrial natriuretic factor precursor (79-98) Proteins 0.000 description 1
• 108010038640 atrial natriuretic factor receptor A Proteins 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 208000002894 beriberi Diseases 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• 229940021459 betaseron Drugs 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 230000007883 bronchodilation Effects 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 210000001054 cardiac fibroblast Anatomy 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 229940106189 ceramide Drugs 0.000 description 1
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
• 229940049197 cerezyme Drugs 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• DKMKCBPTITUZRL-UHFFFAOYSA-L cyclohexane-1,2-diamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.NC1CCCCC1N DKMKCBPTITUZRL-UHFFFAOYSA-L 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000035487 diastolic blood pressure Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 229940053603 elitek Drugs 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000010595 endothelial cell migration Effects 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 230000008556 epithelial cell proliferation Effects 0.000 description 1
• 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000006277 exogenous ligand Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 230000006251 gamma-carboxylation Effects 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 229940063135 genotropin Drugs 0.000 description 1
• 230000001434 glomerular Effects 0.000 description 1
• TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
• 238000007446 glucose tolerance test Methods 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000002308 glutamine derivatives Chemical class 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• 150000003278 haem Chemical group 0.000 description 1
• 230000035931 haemagglutination Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000055277 human IL2 Human genes 0.000 description 1
• 108091016204 human atrial natriuretic factor prohormone (1-30) Proteins 0.000 description 1
• 229940065770 humatrope Drugs 0.000 description 1
• 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002127 imiglucerase Drugs 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000003017 in situ immunoassay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229950000038 interferon alfa Drugs 0.000 description 1
• 108010055511 interferon alfa-2c Proteins 0.000 description 1
• 229940109242 interferon alfa-n3 Drugs 0.000 description 1
• 229960003358 interferon alfacon-1 Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000014828 interferon-gamma production Effects 0.000 description 1
• 230000019734 interleukin-12 production Effects 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• PBZROVYZANOHJC-IGEHTQFKSA-N kaliuretic peptide Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PBZROVYZANOHJC-IGEHTQFKSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 210000000738 kidney tubule Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 description 1
• KAHDONZOCXSKII-UHFFFAOYSA-N kisspeptin-54 Chemical compound C1CCC(C(=O)NC(C)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCCN)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)N2C(CCC2)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CC=2C=CC=CC=2)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2C=CC=CC=2)C(N)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CO)NC(=O)C(NC(=O)C1N(CCC1)C(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C1N(CCC1)C(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCC(O)=O)NC(=O)C1N(CCC1)C(=O)C1N(CCC1)C(=O)C1N(CCC1)C(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(NC(=O)CN)C(C)O)CC1=CNC=N1 KAHDONZOCXSKII-UHFFFAOYSA-N 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 208000006132 lipodystrophy Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000015654 memory Effects 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 230000001114 myogenic effect Effects 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
• 231100000587 neutral red assay Toxicity 0.000 description 1
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229940063137 norditropin Drugs 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 108010028895 oncolipin Proteins 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000000010 osteolytic effect Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 201000009958 panhypopituitarism Diseases 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000013197 protein A assay Methods 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 229960000424 rasburicase Drugs 0.000 description 1
• 229940038850 rebif Drugs 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000021014 regulation of cell growth Effects 0.000 description 1
• 210000002254 renal artery Anatomy 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 102200085943 rs6190 Human genes 0.000 description 1
• 229940063153 saizen Drugs 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 229960002101 secretin Drugs 0.000 description 1
• OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 229940117012 serostim Drugs 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 108700031632 somatrem Proteins 0.000 description 1
• 229960003259 somatrem Drugs 0.000 description 1
• 229960004532 somatropin Drugs 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 230000019635 sulfation Effects 0.000 description 1
• 238000005670 sulfation reaction Methods 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• 239000001648 tannin Substances 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 108010020387 tenascin R Proteins 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 208000012720 thalamic disease Diseases 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 231100000886 tinnitus Toxicity 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229940108519 trasylol Drugs 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 229940005267 urate oxidase Drugs 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 231100000889 vertigo Toxicity 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 230000031836 visual learning Effects 0.000 description 1
• 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 1